文献速递高血压

老年高血压患者强化血压控制的6年STEP试验结果

Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-10-17

STEP试验延长随访显示,持续强化收缩压控制(目标110至<130 mmHg)较延迟强化治疗可降低心血管复合终点事件风险(HR 0.82,95%CI 0.71-0.96)。参数g公式分析提示,随机化时即启动强化治疗的获益最大(RR 0.83,95%CI 0.70-0.96),延迟至12个月启动则获益衰减(RR 0.88,95%CI 0.76-0.99)。

要点

  • 持续强化降压降低主要心血管复合终点风险。
  • 强化治疗启动越早,心血管获益越大。
  • 除低血压外,两组安全事件发生率无差异。

核心结论

  • 长期随访中,持续强化血压控制较延迟强化治疗可降低心血管复合终点事件风险。
  • 高血压诊断后启动强化治疗越早,心血管获益越大。

研究设计与样本

  • STEP试验为随机对照试验,共纳入8511例高血压患者。
  • 患者随机分入强化治疗组(收缩压目标110至<130 mmHg)或标准治疗组(收缩压目标130至<150 mmHg)。
  • 原试验结束后,存活患者进入延长随访期,标准组转为延迟强化治疗组,强化组转为持续强化治疗组。
  • 主要终点为卒中、急性冠脉综合征、急性失代偿性心力衰竭、冠状动脉血运重建、心房颤动或心血管原因死亡的复合终点。

主要发现

  • 中位随访6.11年,持续强化组平均收缩压127.9 mmHg,延迟强化组129.5 mmHg。
  • 持续强化组主要终点年发生率为1.12%,延迟强化组为1.33%(HR 0.82,95%CI 0.71-0.96)。
  • 除低血压外,两组安全事件发生率无差异,低血压在持续强化组更常见。
  • 参数g公式分析显示,与标准治疗相比,随机化时(0个月)启动强化治疗的获益最大(RR 0.83,95%CI 0.70-0.96)。
  • 延迟至12个月启动强化治疗的心血管获益衰减(RR 0.88,95%CI 0.76-0.99)。

关键数值与推荐

  • 强化治疗收缩压目标为110 mmHg至<130 mmHg,标准治疗目标为130 mmHg至<150 mmHg。

临床怎么用

  • 对老年高血压患者,应考虑尽早启动强化血压控制以获取更大心血管获益。
  • 强化降压过程中需监测低血压事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) trial showed that intensive systolic blood pressure (SBP) control reduced cardiovascular risk. OBJECTIVES: Study investigators conducted an extended follow-up of the STEP trial to determine the longer-term effects of intensive blood pressure (BP) control. METHODS: In this randomized controlled trial, 8,511 patients with hypertension were randomly assigned to the intensive treatment group, with an SBP target of 110 mm Hg to <130 mm Hg, or the standard treatment group, with an SBP target of 130 mm Hg to <150 mm Hg. After the original trial ended, all surviving patients, either in the standard group or the intensive treatment group previously, received intensive treatment in the extended period, referred to as the delayed intensive treatment group or the sustained intensive treatment group. The primary outcome was a composite of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death resulting from cardiovascular causes. The Fine-Gray subdistribution hazard model was used to estimate the HR between the 2 groups, and g-formula methods were initiated to compare overall primary outcome risks with intensive treatment initiated from randomization and initiated every year after randomization. RESULTS: After a median follow-up of 6.11 years, the mean SBP was 127.9 mm Hg in the sustained intensive treatment group and 129.5 mm Hg in the delayed intensive treatment group. The incidence rate of primary outcome was 1.12% per year in the sustained intensive treatment group, compared with 1.33% per year in the delayed intensive treatment group (HR: 0.82; 95% CI: 0.71-0.96). No difference in safety event rates between the 2 groups was observed except for hypotension, which occurred more frequently in the sustained intensive treatment group. Furthermore, analyses using the parametric g-formula showed that compared with the standard BP treatment, intensive treatment initiating from randomization (0 month) yielded the greatest benefit (relative risk [RR]: 0.83; 95% CI: 0.70-0.96), with an attenuated cardiovascular benefit for later initiation from 12 months (RR: 0.88; 95% CI: 0.76-0.99). CONCLUSIONS: Our results suggested that sustained intensive BP control could benefit patients with hypertension compared with delayed intensive treatment in the longer-term follow-up. The earlier intensive treatment is initiated after the hypertension diagnosis, the greater the cardiovascular benefits will be. (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients [STEP]; NCT03015311).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Song, Peng, Bai, et al. Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial. J Am Coll Cardiol. 2025. PMID: 41105077. doi:10.1016/j.jacc.2025.06.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。